2-Fluoromethcathinone
 | This article may be too technical for most readers to understand. (November 2024) |
 | |
| Clinical data | |
|---|---|
| Other names | 2-FMC; 2-Fluoromethylcathinone; 2-Fluoro-N-methylcathinone; 2-Flephedrone |
| Drug class | Stimulant; Norepinephrine–dopamine releasing agent |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C10H12FNO |
| Molar mass | 181.210 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
2-Fluoromethcathinone (2-FMC), also known as 2-flephedrone, is a psychostimulant and designer drug of the cathinone family.[1][2][3][4] It acts as a dopamine and norepinephrine releasing agent (NDRA).[4]
Pharmacology
[edit]The drug has an EC50 for dopamine release of 48.7 nM and induces 85% release of norepinephrine at a concentration of 10 μM.[4] For comparison, the EC50 values of methcathinone are 49.9 nM for dopamine release and 22.4 nM for norepinephrine release and it induces 100% release of norepinephrine at a concentration of 10 μM.[4][5] Hence, compared to methcathinone, 2-FMC appears to be relatively more selective or efficacious for induction of dopamine release over norepinephrine release.[4][5] It is notable in this regard that selective dopamine releasing agents are largely unknown.[6][4]
See also
[edit]- 3-Methoxymethcathinone
- 3-Fluoromethcathinone
- 4-Fluoromethcathinone (flephedrone)
- 2-Fluoromethamphetamine
References
[edit]- ^ Kelly JP (2011). "Cathinone derivatives: a review of their chemistry, pharmacology and toxicology". Drug Test Anal. 3 (7–8): 439–453. doi:10.1002/dta.313. PMID 21755607.
- ^ Glennon RA (2014). "Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention". Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse. Adv Pharmacol. Vol. 69. pp. 581–620. doi:10.1016/B978-0-12-420118-7.00015-9. ISBN 978-0-12-420118-7. PMC 4471862. PMID 24484988.
- ^ Kelleher C, Christie R, Lalor K, Fox J, Bowden M, O'Donnell C (30 June 2011). "An Overview of New Psychoactive Substances and the Outlets Supplying them". Reports. doi:10.21427/43F1-XR91. Retrieved 24 November 2024.
- ^ a b c d e f Blough BE, Decker AM, Landavazo A, Namjoshi OA, Partilla JS, Baumann MH, et al. (March 2019). "The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes". Psychopharmacology (Berl). 236 (3): 915–924. doi:10.1007/s00213-018-5063-9. PMC 6475490. PMID 30341459.
- ^ a b Blough B (July 2008). "Dopamine-releasing agents" (PDF). In Trudell ML, Izenwasser S (eds.). Dopamine Transporters: Chemistry, Biology and Pharmacology. Hoboken [NJ]: Wiley. pp. 305–320. ISBN 978-0-470-11790-3. OCLC 181862653. OL 18589888W.
- ^ Negus SS, Mello NK, Blough BE, Baumann MH, Rothman RB (February 2007). "Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate "agonist" medications for cocaine dependence: studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys". J Pharmacol Exp Ther. 320 (2): 627–636. doi:10.1124/jpet.106.107383. PMID 17071819.